23 May 2018
AWS Seed Financing awarded to Morphomed for Development of RegACL
About MorphoMed
MorphoMed, a privately held MedTech Start-Up company founded in Vienna in May 2017 is focused on the development of new regenerative implants based on its proprietary medical silk technology. Silk can be completely cleaned from its antigenic sericin layer even in complex textile structures such as a braided ACL (anterior cruciate ligament). Based on its lead product RegACL Morphomed plans to establish a portfolio of implants for orthopedic and general surgery thus inducing full regeneration of their body’s own natural tissue.
MorphoMed is an associate member of the Austrian Cluster for Tissue Regeneration.
Contact
Dr. Michael Jakusch, CEO
MorphoMed GmbH
office@morphomed.at
www.morphomed.at
AWS Seed Financing awarded to Morphomed for Development of RegACL
In spring 2018 the AWS Seed funding was granted to Morphomed for its development program. After an evaluation period of over 6 months and a successful jury board decision, the funding was granted, all contracts closed and the first payment transferred. With the Seed financing, the company´s lead product “RegACL” will be supported. Reg ACL is a regenerative anterior cruciate ligament from highly purified silk, which acts as a scaffold and fully restores original ligament. The development program, includes the establishment of a commercial manufacturing process, biocompatibility testing and a clinical study. “We see the AWS as a strong partner, their support goes far beyond the pure financial part”, argues Dr. Küenburg, CEO.
MorphoMed, a privately held MedTech Start-Up company founded in Vienna in May 2017 is focused on the development of new regenerative implants based on its proprietary medical silk technology. Silk can be completely cleaned from its antigenic sericin layer even in complex textile structures such as a braided ACL (anterior cruciate ligament). Based on its lead product RegACL Morphomed plans to establish a portfolio of implants for orthopedic and general surgery thus inducing full regeneration of their body’s own natural tissue.
MorphoMed is an associate member of the Austrian Cluster for Tissue Regeneration.
Contact
Dr. Michael Jakusch, CEO
MorphoMed GmbH
office@morphomed.at
www.morphomed.at
